Yung Lyou, MD, UC Irvine Health, talks about Keynote 61 Trial | See if Pembrolizumab Can be Moved to the 2nd-line Setting at MOASC 2018
Keynote 61 Trial | See if Pembrolizumab Can be Moved to the 2nd-line Setting
Yung Lyou, MD, UC Irvine Health, talks about Keynote 61 Trial | See if Pembrolizumab Can be Moved to the 2nd-line Setting at MOASC 2018